HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Often unrecognized, depression can be a debilitating side effect of cancer
-
- 12-week warfarin assessment noninferior to 4-week assessment
- Biomarkers identified to predict benefit from maintenance erlotinib
- CC genotype associated with sustained virologic response to HCV
- Changes coming to allergy immunotherapy
- Coffee consumption linked to lower risk for basal cell carcinoma
- Computer program improved communication between oncologists, patients
- EGFR expression identified greatest cetuximab benefit in patients with NSCLC
- FDA approves cetuximab for metastatic head and neck cancer
-
- FDA approves first cord blood treatment
- FDA revokes indication for bevacizumab in metastatic breast cancer
- Fecal immunochemical test good alternative when colonoscopy capacity limited
- Increased dietary fiber, whole grain intake reduced colorectal cancer risk
- MITF may be an oncogene for familial, sporadic melanoma
- Novel steroidal compound has clinical activity in advanced breast cancer
- Older, sicker patients less likely to get recommended therapies
- Pharmacogenomic testing consent failed to yield selection bias
-
- Reduced alcohol consumption during adolescence may decrease breast cancer risk
- Reduced-intensity heparin may decrease VTE recurrence
- Rituximab plus chemotherapy improved survival in mantle cell lymphoma
- Vaccine may be active in breast, ovarian cancers
- Progression of prostate cancer in an 80-year-old male Amit Mehta, MD
- FDA approves orphan drug status for ruxolitinib
- Multidisciplinary program bested traditional method in HCV treatment
- Metastatic breast carcinoma with mixed response to therapy Munir Ghesani, MD, FACNM; Gabriel Sara, MD; Sumit Talwar, MD; Eaton Lin, MD
-
- Addition of radiation to ADT improved OS in locally advanced prostate cancer
- Epigenetic therapy improved PFS, OS in NSCLC
- Fewer nitrates in hot dogs possibly linked to reduced colon cancer deaths
- Prostatectomy outcomes better at academic institutions
- R1507 provided no advantage over erlotinib for advanced NSCLC
- VEGF-inhibitor axitinib valid second-line treatment for RCC
- Dietary patterns associated with increased C-peptide, colorectal cancer risk in women
- Skin cancer risk increased along with tanning bed use
-
- Guidelines can help identify unmet palliative care needs Biren Saraiya, MD